Gain Therapeutics (NASDAQ:GANX) Announces Quarterly Earnings Results

Gain Therapeutics (NASDAQ:GANX) posted its quarterly earnings data on Tuesday. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.05, Zacks reports.

Gain Therapeutics Stock Performance

GANX stock traded down $0.01 during midday trading on Thursday, reaching $1.10. The company had a trading volume of 90,299 shares, compared to its average volume of 706,602. The firm has a market capitalization of $47.88 million, a PE ratio of -2.61 and a beta of 0.29. The stock has a 50 day moving average price of $1.50 and a 200 day moving average price of $1.83. Gain Therapeutics has a fifty-two week low of $0.94 and a fifty-two week high of $4.34. The company has a quick ratio of 4.36, a current ratio of 4.36 and a debt-to-equity ratio of 0.02.

Analysts Set New Price Targets

Several research firms have recently commented on GANX. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, October 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Gain Therapeutics in a report on Friday, September 4th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $5.00 price target on shares of Gain Therapeutics in a report on Monday, October 5th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $7.67.

About Gain Therapeutics

Gain Therapeutics, Inc. is a biotechnology company focused on developing small-molecule therapies for diseases associated with lysosomal dysfunction, including neurodegenerative and rare disorders. The company’s approach is designed to identify compounds that bind to and modulate disease-related proteins, with the goal of restoring their function and addressing underlying disease mechanisms. Gain Therapeutics’ lead investigational program, GT-02287, is an orally administered, brain-penetrant small molecule being developed for GBA1-associated Parkinson’s disease.